Concizumab, an IgG4 subtype monoclonal antibody, targets the Kunitz-type protease inhibitor 2 (KPI-2) structural domain of tissue factor pathway inhibitor (TFPI). By binding to this domain, Concizumab effectively inhibits the interaction between TFPI and the Factor Xa (FXa) active site. This antibody is particularly useful for research in hemophilia, providing insights into novel therapeutic interventions targeting coagulation pathways.
Concizumab, an IgG4 subtype monoclonal antibody, targets the Kunitz-type protease inhibitor 2 (KPI-2) structural domain of tissue factor pathway inhibitor (TFPI). By binding to this domain, Concizumab effectively inhibits the interaction between TFPI and the Factor Xa (FXa) active site. This antibody is particularly useful for research in hemophilia, providing insights into novel therapeutic interventions targeting coagulation pathways.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
